Impact of serogroup A meningococcal conjugate vaccine for Africa
The introduction of a serogroup A meningococcal conjugate vaccine in the African meningitis belt has been a remarkable success. Meningitis due to the serogroup A meningococcus, previously responsible for most epidemics, has fallen by 99% in vaccinated countries. Success must, however, not distract f...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Taylor & Francis Group
2018-05-01
|
| Sarja: | Human Vaccines & Immunotherapeutics |
| Aiheet: | |
| Linkit: | http://dx.doi.org/10.1080/21645515.2017.1412022 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|